# EDGAR Filing Document

**Accession Number:** 0002020932
**File Stem:** 0001104659-26-066590
**Filing Date:** 2026-5
**Character Count:** 5602
**Document Hash:** ac4a9c858e594f9684e967789966ec7b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-066590.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001104659-26-066590

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260527

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Agomab Therapeutics NV
- **CENTRAL INDEX KEY:** 0002020932
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43098
- **FILM NUMBER:** 261022150

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600
- **BUSINESS PHONE:** 32 3 302 35 30

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of**

**the Securities Exchange Act of 1934**

**For the month of May 2026**

**Commission File Number: 001-07291**

**AgomAb Therapeutics NV**

**Posthoflei 1/6**

**2600 Antwerpen**

**Belgium**

**Tel: +32 3 318 91 70**

(Address, Including Zip Code, and Telephone Number,<br> Including Area Code, of Registrant's Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

On May 27, 2026, AgomAb Therapeutics NV (the "Company") issued a press release titled, "Agomab Announces Results of Annual General Meeting," announcing the results of the Company's Annual General Meeting held on May 26, 2026. A copy of this press release is furnished hereto as Exhibit 99.1.

*The information contained in Exhibit 99.1 to this Form 6-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.*

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| **Number** | **Description** |
| [99.1](tm2615659d1_ex99-1.htm) | [Press Release of AgomAb Therapeutics NV dated May 27, 2026, announcing the results of the Company's Annual General Meeting held on May 26, 2026.](tm2615659d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AgomAb Therapeutics NV** | **AgomAb Therapeutics NV** |
| Date: May 27, 2026 | By: | /s/ Tim Knotnerus |
|  |  | Tim Knotnerus |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2615659d1_ex99-1img001.jpg)

**Agomab Announces Results of Annual General Meeting**

**Antwerp, Belgium,** **May 27, 2026** – <u>Agomab Therapeutics NV</u> (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.

All items on the agenda were approved, including:

&nbsp;&nbsp;&nbsp;&nbsp;· Approval
 of the statutory financial statements for the financial year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;· Discharge
 to the current and former members of the Board of Directors and the statutory auditor in
 respect of the performance of their respective duties during the financial year ending on
 December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;· Reappointment
 of Mr. Ohad Hammer as a member of the Board of Directors for a term of one year.

&nbsp;&nbsp;&nbsp;&nbsp;· Reappointment
 of Mr. Tim Knotnerus as a member of the Board of Directors for a term of four years.

The voting result and all documents relating to the shareholders' meeting are available on the Agomab investor relations website at https://ir.agomab.com/governance/shareholder-meetings.

**About Agomab**

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab's product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab's mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

**Contacts**

**Investors**

Sofie Van Gijsel

VP of Investor Relations

E-mail: <u>sofie.vangijsel@agomab.com</u>

Phone: +1 781 296 1143

**Media**

Gretchen Schweitzer

Trophic Communications

E-mail: <u>agomab@trophic.eu</u>

Phone: +49 172 861 8540